Latest filingSep 04, 2026Most recent Form 4
SYRE
Spyre Therapeutics, Inc.
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$607M14 sells
Net open-market-$607M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period20transactions
- S · Open-market sells · dominant14 · 70%
- M · Option exercise6 · 30%
Activity by reported role
A joint filing can contribute to multiple roles20transactions
- SR · dominant9 · 45%
- Chief financial officer7 · 35%
- Chief executive officer4 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeKing-Jones HeidyCommon Stock · Direct
2,845Sep 02, 2026
Burrows Scott LCommon Stock · Direct
79,762Sep 02, 2026
Turtle CameronCommon Stock · Direct
565,040Sep 01, 2026
King-Jones HeidyStock Option (Right to Buy) · Direct
511,411Sep 02, 2026
Burrows Scott LStock Option (Right to Buy) · Direct
337,357Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- BL-$2.2M
- KH-$2.1M
- TC-$1.3M
Recent filing activity
Most recent 12 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
SYRE transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| SYRE | King-Jones Heidy | SR | exercise10b5-1 | 400 | $0 | M | — | 0.0% | 09/04 | 09/02 |
| SYRE | King-Jones Heidy | SR | exercise10b5-1 | 27.9k | $0 | M | — | 0.0% | 09/04 | 09/01 |
| SYRE | King-Jones Heidy | SR | sale10b5-1 | 400 | -$3.60M | S | — | 0.0% | 09/04 | 09/02 |
| SYRE | King-Jones Heidy | SR | exercise10b5-1 | 400 | $580k | M | — | 0.0% | 09/04 | 09/02 |
| SYRE | King-Jones Heidy | SR | sale10b5-1 | 400 | -$3.57M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | King-Jones Heidy | SR | sale10b5-1 | 6.20k | -$54.7M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | King-Jones Heidy | SR | sale10b5-1 | 16.5k | -$144M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | King-Jones Heidy | SR | sale10b5-1 | 4.84k | -$41.8M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | King-Jones Heidy | SR | exercise10b5-1 | 27.9k | $40.5M | M | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | exercise10b5-1 | 7.50k | $0 | M | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | sale10b5-1 | 18.2k | -$162M | S | — | 0.0% | 09/04 | 09/02 |
| SYRE | Burrows Scott L | CFO | sale10b5-1 | 200 | -$1.78M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | sale10b5-1 | 2.01k | -$17.7M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | sale10b5-1 | 4.38k | -$38.1M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | sale10b5-1 | 900 | -$7.76M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Burrows Scott L | CFO | exercise10b5-1 | 7.50k | $10.8M | M | — | 0.0% | 09/04 | 09/01 |
| SYRE | Turtle Cameron | CEO | sale10b5-1 | 400 | -$3.56M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Turtle Cameron | CEO | sale10b5-1 | 3.70k | -$32.5M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Turtle Cameron | CEO | sale10b5-1 | 8.40k | -$73.2M | S | — | 0.0% | 09/04 | 09/01 |
| SYRE | Turtle Cameron | CEO | sale10b5-1 | 2.50k | -$21.5M | S | — | 0.0% | 09/04 | 09/01 |
Spyre Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Spyre Therapeutics, Inc.?
King-Jones Heidy, Burrows Scott L, Turtle Cameron.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
King-Jones Heidy reported a sale on Sep 02, 2026 valued at $3.60M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $6,073,759.54. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.